eng-CAN-male;jmk	1d77be3e5b13c187a910bb99c9e3e261
eng-DEU-male;ahw	77a00757031f91f722bc9bc66b9a972b
eng-DEU-male;fem	481358d1e88bc99f92e851a00e2b2bff
eng-GBR-male;awb	4d16d8bdefd2e3dea01b5756ec845f31
eng-IND-female;axb	b3217e464f742a241a6f1a09f8cb7a00
eng-IND-male;aup	4d3b7720998fdec0e218dfd68458543e
eng-IND-male;gka	831562fd2b1368479b11406593adf262
eng-IND-male;ksp	3fd0a65def75a533405c4cc230e2d255
eng-ISR-male;rxr	be587a05d2a9eecf72218d1ff1d67b08
eng-USA-female;clb	71a9cce0157be58c944f4fdf3470373a
eng-USA-female;eey	4abd8bab4535b3bf7ba880d33d425e77
eng-USA-female;ljm	32f50460bf126e4f52c09ea6c2e6b422
eng-USA-female;slt	a65f309e638ceeca6548a817fc285f1f
eng-USA-male;aew	b93e0d3e259122f00a0b5d4f118e7580
eng-USA-male;bdl	d654bb92b3b1d548ef2c58b28a5f0fec
eng-USA-male;rms	2485ee075a2e0f34ff9b4edb12d407d9
guj-IND-female;axb	3e0fb63f6faee3b1d751bc31697b469e
hin-IND-female;axb	34dc7e7d5c92b398d357d1f67411249f
mar-IND-female;slp	67f7b92248845b5eac18a4e52b6ef493
tam-IND-female;sxv	af7393cab410ff3d61f1314bd11f3034
tel-IND-female;knr	e36c5e7e726aa7dd6aa44fb4e95605f9
